4.4 Article

Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics

Journal

CLINICAL & TRANSLATIONAL ONCOLOGY
Volume 13, Issue 9, Pages 617-628

Publisher

SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s12094-011-0707-9

Keywords

Genomics; Proteomics; Metabolomics; Bioinformatics

Categories

Funding

  1. Ministerio de Ciencia e Innovacion [SAF2008-03750, RD06-0020-0016]

Ask authors/readers for more resources

Recent technological advances, combined with the development of bioinformatic tools, allow us to better address biological questions combining -omic approaches (i.e., genomics, metabolomics and proteomics). This novel comprehensive perspective addresses the identification, characterisation and quantitation of the whole repertoire of genes, proteins and metabolites occurring in living organisms. Here we provide an overview of recent significant advances and technologies used in genomics, metabolomics and proteomics. We also underline the importance and limits of mass accuracy in mass spectrometry-based -omics and briefly describe emerging types of fragmentation used in mass spectrometry. The range of instruments and techniques used to address the study of each -omic approach, which provide vast amounts of information (usually termed 'high-throughput' technologies in the literature) is briefly discussed, including names, links and descriptions of the main databases, data repositories and resources used. Integration of multiple -omic results and procedures seems necessary. Therefore, an emerging challenge is the integration of the huge amount of data generated and the standardisation of the procedures and methods used. Functional data integration will lead to answers to unsolved questions, hopefully, applicable to clinical practice and management of patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Multidisciplinary Sciences

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

Arancha Cebrian, Teresa Gomez del Pulgar, Maria Jose Mendez-Vidal, Maria Luisa Gonzalvez, Nuria Lainez, Daniel Castellano, Iciar Garcia-Carbonero, Emilio Esteban, Maria Isabel Saez, Rosa Villatoro, Cristina Suarez, Alfredo Carrato, Javier Munarriz-Ferrandiz, Laura Basterrechea, Mirta Garcia-Alonso, Jose Luis Gonzalez-Larriba, Begona Perez-Valderrama, Josefina Cruz-Jurado, Aranzazu Gonzalez del Alba, Fernando Moreno, Gaspar Reynes, Maria Rodriguez-Remirez, Valentina Boni, Ignacio Mahillo-Fernandez, Yolanda Martin, Andrea Viqueira, Jesus Garcia-Foncillas

SCIENTIFIC REPORTS (2017)

Article Oncology

Prognostic significance of neutrophil-to lymphocyte ratio and platelet-to lymphocyte ratio in older patients with metastatic colorectal cancer

Marlid Cruz-Ramos, Laura del Puerto-Nevado, Binbin Zheng, Rafael Lopez-Bajo, Arancha Cebrian, Maria Rodriguez-Remirez, Laura Garcia-Garcia, Sonia Solanes-Casado, Jesus Garcia-Foncillas

JOURNAL OF GERIATRIC ONCOLOGY (2019)

Article Oncology

TRIM72 Immunohistochemical Expression Can Predict Relapse in Colorectal Carcinoma

M. J. Fernandez-Acenero, M. Cruz, J. Sastre-Varela, J. Casal, M. A. Ceron Nieto, L. del Puerto-Nevado, J. Garcia-Foncillas, A. Cebrian

PATHOLOGY & ONCOLOGY RESEARCH (2020)

Article Cell Biology

Choline Uptake and Metabolism Modulate Macrophage IL-1β and IL-18 Production

Elsa Sanchez-Lopez, Zhenyu Zhong, Alexandra Stubelius, Shannon R. Sweeney, Laela M. Booshehri, Laura Antonucci, Ru Liu-Bryan, Alessia Lodi, Robert Terkeltaub, Juan Carlos Lacal, Anne N. Murphy, Hal M. Hoffman, Stefano Tiziani, Monica Guma, Michael Karin

CELL METABOLISM (2019)

Article Endocrinology & Metabolism

Strong Antitumor Activity of Bevacizumab and Aflibercept in Neuroendocrine Carcinomas: In-Depth Preclinical Study

Maria Rodriguez-Remirez, Laura del Puerto-Nevado, Maria Jesus Fernandez Acenero, Hakimeh Ebrahimi-Nik, Marlid Cruz-Ramos, Laura Garcia-Garcia, Sonia Solanes, Natalia Banos, Elena Molina-Roldan, Jesus Garcia-Foncillas, Arancha Cebrian

NEUROENDOCRINOLOGY (2020)

Article Microbiology

Choline Kinase Emerges as a Promising Drug Target in Gram-Positive Bacteria

Tahl Zimmerman, Juan Carlos Lacal, Salam A. Ibrahim

FRONTIERS IN MICROBIOLOGY (2019)

Article Endocrinology & Metabolism

Targeting Galectin-1 by Aflibercept Strongly Enhances Its Antitumor Effect in Neuroendocrine Carcinomas

Maria Rodriguez-Remirez, Laura del Puerto-Nevado, Maria Jesus Fernandez-Acenero, Marlid Cruz-Ramos, Laura Garcia-Garcia, Sonia Solanes, Elena Molina-Roldan, Jesus Garcia-Foncillas, Arancha Cebrian

NEUROENDOCRINOLOGY (2020)

Article Multidisciplinary Sciences

Identification and validation of novel and more effective choline kinase inhibitors against Streptococcus pneumoniae

Tahl Zimmerman, Valerie Chasten, Juan Carlos Lacal, Salam A. Ibrahim

SCIENTIFIC REPORTS (2020)

Article Oncology

Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes

Barbara Manzanares-Martin, Arancha Cebrian Aranda, Laura del Puerto-Nevado, Rafael Gonzalez, Sonia Solanes, Maria Auxiliadora Gomez-Espana, Jesus Garcia-Foncillas, Enrique Aranda

Summary: The study investigated the potential value of KIR genotyping in the clinical outcome of patients with KRAS mutant mCRC treated with cetuximab. The results demonstrated the immunomodulatory activity of cetuximab in KRAS mutant mCRC patients and identified KIR genotypes as an independent predictor of patient outcomes.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Review Pharmacology & Pharmacy

Choline Kinase: An Unexpected Journey for a Precision Medicine Strategy in Human Diseases

Juan Carlos Lacal, Tahl Zimmerman, Joaquin M. Campos

Summary: Choline kinase plays a crucial role in human tumors and specific compounds targeting it have been identified as potential anticancer agents. Some of these compounds have shown selective anticancer activity and have progressed to clinical trials. Additionally, ChoK alpha inhibitors are proposed as a novel therapeutic approach against various diseases.

PHARMACEUTICS (2021)

Review Biochemistry & Molecular Biology

The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases

Angel M. Cuesta, Eunate Gallardo-Vara, Juan Casado-Vela, Lucia Recio-Poveda, Luisa-Maria Botella, Virginia Albinana

Summary: Rare Diseases (RD), although individually may seem insignificant, collectively represent over 7000 different diseases that pose a life-threatening condition for patients. Drug repurposing, an alternative option in drug development, has been identified as a viable strategy to tackle RDs. Propranolol, initially prescribed for hypertension and other conditions, has shown promising therapeutic effects in RDs, including antiangiogenic, pro-apoptotic, vasoconstrictor, and anti-inflammatory properties.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Medicine, General & Internal

A Novel Splicing Mutation in the ACVRL1/ALK1 Gene as a Cause of HHT2

Suriel Errasti Diaz, Mercedes Penalva, Lucia Recio-Poveda, Susana Vilches, Juan Casado-Vela, Julian Perez Perez, Luisa Maria Botella, Virginia Albinana, Angel M. Cuesta

Summary: Hereditary Hemorrhagic Telangiectasia (HHT) is a rare disorder characterized by vascular development abnormalities. This study identified a novel mutation in the ACVRL1/ALK1 gene, leading to reduced ALK1 protein levels. The mutation can be diagnosed using genetic sequencing, providing a simple diagnostic method for developing countries.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Pharmacology & Pharmacy

Choline Kinase α Inhibitors MN58b and RSM932A Enhances the Antitumor Response to Cisplatin in Lung Tumor Cells

Juan Carlos Lacal, Rosario Perona, Javier de Castro, Arancha Cebrian

Summary: Lung cancer is a leading cause of mortality in developed countries. Immunotherapy has been proposed as a standard treatment for advanced non-small cell lung cancer (NSCLC), but there is a need for novel strategies to improve patient outcomes. Choline kinase alpha (ChoK alpha) has been identified as a potential target for cancer therapy. Combining ChoK alpha inhibitors with platinum-based chemotherapy may offer a new and effective treatment approach for NSCLC patients.

PHARMACEUTICS (2022)

Review Medicine, General & Internal

Propranolol: A Pick and Roll Team Player in Benign Tumors and Cancer Therapies

Virginia Albinana, Eunate Gallardo-Vara, Juan Casado-Vela, Lucia Recio-Poveda, Luisa Maria Botella, Angel M. Cuesta

Summary: Research on cancer therapies focuses on various processes influenced by the cellular and molecular microenvironment of the tumor. Different strategies, including the use of propranolol, have been tested to reduce malignancy and create a harmful microenvironment for the tumor. Propranolol has shown antitumoral properties and synergistic effects when used in combination with other drugs.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Medicine, Research & Experimental

Galectin-1, a novel promising target for outcome prediction and treatment in SCLC

Juan Manuel Corral, Laura del Puerto-Nevado, Mabel Cedeno, Anxo Rio-Vilarino, Ignacio Mahillo-Fernandez, Carlos Galeano, Natalia Banos, Jesus Garcia-Foncillas, Manuel Domine, Arancha Cebrian

Summary: This study found that high levels of Gal-1 and PLR were associated with poorer prognosis in SCLC patients, supporting their utility as clinical prognostic biomarkers. Additionally, an in vivo model suggested that inhibition of Gal-1 may be a novel potential therapy for this disease with very poor prognosis.

BIOMEDICINE & PHARMACOTHERAPY (2022)

No Data Available